


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:


Claim 1. (Currently amended) A compound represented by the general formula I



wherein

R^1 , R^2 , R^3 , R^4 , R^5 are independently selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)oxy, C_{1-6} -alk(en/yn)ylsulfanyl, hydroxy, hydroxy- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)oxy, or and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, or and NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, or and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; or

R^2 and R^3 together ~~form a heterocycle fused to~~ with the the phenyl ring selected from to which they are attached form the structure represented by the formula



R⁶, R⁷, R⁸, R⁹ are independently selected from the group consisting of hydrogen, halogen, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yloxy, or and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, or and NR^zR^w-C₁₋₆-alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, or and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom;

provided that at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ is different from hydrogen; also provided that when R³ is methyl or methoxy, then at least one of R¹, R², R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ is different from hydrogen;
 or a pharmaceutically acceptable salt thereof.


Claim 2. (Currently amended) The compound of claim 1, wherein R¹ is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, halo-C₁₋₆-alk(en/yn)yl, and or NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, and or NR^zR^w-C₁₋₆-alk(en/yn)yl, wherein R^z and R^w are independently

selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, and or C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w-C₁₋₆-alk(en/yn)yl then the other is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, and or C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; typically, R¹ is selected from hydrogen, C₁₋₆-alkyl, halogen, C₁₋₆-alkyloxy, or halo-C₁₋₆-alkyl; more typically, R¹ is selected from hydrogen, C₁₋₆-alkyl, or halogen.

Claim 3. (Currently amended) The compound of ~~any one of claims 1-2~~ claim 1, wherein R² is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl, and halo-C₁₋₆-alk(en/yn)yl; typically, R² is selected from hydrogen, C₁₋₆-alkoxy, halogen, C₁₋₆-alkyl, or halo-C₁₋₆-alkyl; more typically, R² is selected from hydrogen, or C₁₋₆-alkoxy.

Claim 4. (Currently amended) The compound of ~~any one of claims 1-3~~ claim 1, wherein R³ is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl, and halo-C₁₋₆-alk(en/yn)yl; typically, R³ is selected from hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, halogen, C₁₋₆-alkylsulfanyl, halo-C₁₋₆-alkyl, or halo-C₁₋₆-alkyloxy; more typically, R³ is selected from hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, or halogen.

Claim 5. (Currently amended) The compound of ~~any one of claims 1-2~~ claim 1, wherein R² and R³ together form a heterocycle fused to with the phenyl ring selected from to which they are attached form the structure represented by the formula



Claim 6. (Currently amended) The compound of ~~any one of claims 1-5~~ claim 1 wherein R⁴ is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)ylloxy, C₁₋₆-alk(en/yn)ylsulfanyl, and halo-C₁₋₆-alk(en/yn)yl; ~~typically, R⁴ is selected from hydrogen, C₁₋₆-alkoxy, halogen, C₁₋₆-alkyl, or halo-C₁₋₆-alkyl; more typically, R⁴ is selected from hydrogen, or C₁₋₆-alkoxy.~~

Claim 7. (Currently amended) The compound of ~~any one of claims 1-6~~ claim 1 wherein R⁵ is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)ylloxy, C₁₋₆-alk(en/yn)ylsulfanyl, halo-C₁₋₆-alk(en/yn)yl, ~~or~~ and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, ~~or~~ and NR^zR^w-C₁₋₆-alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, ~~or~~ and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w-C₁₋₆-alk(en/yn)yl then the other is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, ~~or~~ and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; ~~typically, R⁵ is selected from hydrogen, C₁₋₆-alkyl, halogen, C₁₋₆-alkyloxy, or halo-C₁₋₆-alkyl; more typically, R⁵ is selected from hydrogen, C₁₋₆-alkyl, or halogen.~~

Claim 8. (Currently amended) The compound of ~~any one of claims 1-7~~ claim 1 wherein R^6 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, and halo- C_{1-6} -alk(en/yn)yl; ~~typically, R^6 is selected from hydrogen, or halogen.~~

Claim 9. (Currently amended) The compound of ~~any one of claims 1-8~~ claim 1 wherein R^7 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, and halo- C_{1-6} -alk(en/yn)yl; ~~typically, R^7 is selected from hydrogen, or halogen.~~

Claim 10. (Currently amended) The compound of ~~any one of claims 1-9~~ claim 1 wherein R^8 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, ~~or~~ and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, ~~or~~ and NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, ~~or~~ and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w - C_{1-6} -alk(en/yn)yl then the other is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, ~~or~~ and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; ~~typically, R^8 is selected from hydrogen, C_{1-6} -alkyl, halogen, halo- C_{1-6} -alkyl, or NR^xR^y wherein R^x is hydrogen and R^y is C_{1-6} -alkyl; more typically, R^8 is selected from hydrogen, C_{1-6} -alkyl, halogen, or halo- C_{1-6} -alkyl.~~

Claim 11. (Currently amended) The compound of ~~any one of claims 1-10~~ claim 1 wherein R^9 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, and halo- C_{1-6} -alk(en/yn)yl; ~~typically, R^9 is selected from hydrogen.~~

Claim 12. (Currently amended) The compound of ~~any one of claims 1-11~~ claim 1 wherein the compound of formula I has 1-4 substituents in the phenyl ring(s), selected

from any one of R¹-R⁹, which are different from hydrogen, and the remaining substituents are hydrogen.

Claim 13. (Currently amended) ~~The A compound of claim 1, said compound being selected from the group consisting of:~~

4-[2-(4-Fluorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chlorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Methoxyphenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
4-(5-Methyl-2-p-tolylsulfanylphenyl)-1,2,3,6-tetrahydropyridine,
4-[2-(4-Fluorophenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chlorophenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2,4-Dimethylphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chlorophenylsulfanyl)-5-trifluoromethyl-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Fluoro-2-methylphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chlorophenylsulfanyl)-4-fluoro-phenyl]-1,2,3,6-tetrahydropyridine,
4-[4-Fluoro-2-(p-tolylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[4-Fluoro-2-(4-methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2,4-Dimethylphenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2,4-Dimethylphenylsulfanyl)-5-trifluoromethyl-phenyl]-1,2,3,6-tetrahydropyridine,
4-(2-p-Tolylsulfanyl-5-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine,
4-[2-(4-Fluoro-2-methylphenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydropyridine,
4-[5-Bromo-2-(2,4-dimethylphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chlorophenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydropyridine,
4-[5-Fluoro-2-(4-methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2,4-Dichlorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chloro-2-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(3-Methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[3-Fluoro-2-(4-methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2-Chlorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2-Chloro-4-methoxyphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,

4-[2-(2-Fluorophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2-Bromophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Bromophenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-(2-o-Tolylsulfanylphenyl)-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chloro-2-methylphenylsulfanyl)-phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,3-Dichloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,3-Dimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3,4-Dimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Methoxy-5-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-4-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Methoxy-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Fluoro-4-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,4-Dimethyl-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-(5-Fluoro-2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
4-[5-Fluoro-2-(4-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-(2-m-Tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Fluoro-3-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Bromo-4-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-4-fluoro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,4-Dichloro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Chloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,4-Dichloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Chloro-2-fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Chloro-2-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Fluoro-4-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,4-Difluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-4-fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Bromo-4-fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,

4-[2-(2-Bromo-4-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Bromo-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Bromo-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-(5-Methyl-2-o-tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Methoxy-2-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Fluoro-4-methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3,4-Dichloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-4-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Fluoro-4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3,4-Dichloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Bromo-2-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Bromo-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,4-Difluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Bromo-4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Chloro-2-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[5-Fluoro-2-(2-fluoro-4-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-4-methoxy-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[5-Fluoro-2-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-4-methyl-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Chloro-2-fluoro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[5-Fluoro-2-(4-methoxy-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,3-Dimethyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[5-Methyl-2-(3-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3,4-Dimethyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Chloro-2-methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,3-Difluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-4-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,3-Difluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,

4-[2-(3-Chloro-2-fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Fluoro-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Chloro-2-methyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Fluoro-2-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Fluoro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Chloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Bromo-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[5-Methyl-2-(3-trifluoromethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Ethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Ethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-tert-Butyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-tert-Butyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Trifluoromethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Trifluoromethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Trifluoromethoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Methylsulfanyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3,5-Dimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,5-Dimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,5-Dichloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3,5-Dichloro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,4,6-Trimethyl-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[5-Methylamino-2-(4-methyl-~~phenylsulfanyl~~phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-
pyridine,
4-[5-Fluoro-2-(2-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-(5-Fluoro-2-o-tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
4-(5-Fluoro-2-p-tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,

4-[2-(Benzo[1,3]dioxol-5-ylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-4-methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2,3-Dichloro-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Chloro-2-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(Benzo[1,3]dioxol-5-ylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[5-Fluoro-2-(3-fluoro-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-(5-Fluoro-2-m-tolylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyridine,
4-[5-Fluoro-2-(3-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Chloro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(2-Chloro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[4-Fluoro-2-(4-methyl- ~~phenylsulfanyl~~ phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-
pyridine,
4-[2-(4-Bromo-2-fluoro-phenylsulfanyl)-5-fluoro-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(4-Fluoro-3-methoxy-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
4-[2-(3-Fluoro-4-methyl-phenylsulfanyl)-5-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine,
and
4-[5-Fluoro-2-(4-methoxy-phenylsulfanyl)-phenyl]-1,2,3,6-tetrahydro-pyridine[[,]];
or a pharmaceutically acceptable salt thereof.

Claim 14. (Currently amended) A pharmaceutical composition comprising a compound
of ~~any one of claims 1-13~~ claim 1 or a pharmaceutically acceptable ~~acid-addition~~ salt
thereof and at least one pharmaceutically acceptable carrier or diluent.

Claim 15. (Cancelled)

Claim 16. (Currently amended) A method for the treatment of an affective disorder,
~~such as depression, anxiety disorder[[s]] including general anxiety disorder, social~~
~~anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, panic~~
~~disorder, panic attacks, specific phobias, social phobia and agoraphobia in a living~~
~~animal body, including a human,~~ comprising administering to a subject a

therapeutically effective amount of a compound of ~~any one of claims 1-13~~ claim 1 or a pharmaceutically acceptable ~~acid-addition~~ salt thereof.

Claim 17. (Cancelled)

Claim 18. (New) The compound of claim 2 wherein R^1 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -alkyloxy, and halo- C_{1-6} -alkyl.

Claim 19. (New) The compound of claim 18 wherein R^1 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, and halogen

Claim 20. (New) The compound of claim 3 wherein R^2 is selected from the group consisting of hydrogen, C_{1-6} -alkoxy, halogen, C_{1-6} -alkyl, and halo- C_{1-6} -alkyl.

Claim 21. (New) The compound of claim 20 wherein R^2 is selected from the group consisting of hydrogen and C_{1-6} -alkoxy.

Claim 22. (New) The compound of claim 4 wherein R^3 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, halogen, C_{1-6} -alkylsulfanyl, halo- C_{1-6} -alkyl, and halo- C_{1-6} -alkyloxy.

Claim 23. (New) The compound of claim 22 wherein R^3 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, and halogen.

Claim 24. (New) The compound of claim 6 wherein R^4 is selected from the group consisting of hydrogen, C_{1-6} -alkoxy, halogen, C_{1-6} -alkyl, and halo- C_{1-6} -alkyl.

Claim 25. (New) The compound of claim 24 wherein R^4 is selected from the group consisting of hydrogen and C_{1-6} -alkoxy.

Claim 26. (New) The compound of claim 7 wherein R^5 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -alkyloxy, and halo- C_{1-6} -alkyl.

Claim 27. (New) The compound of claim 26 wherein R^5 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, and halogen.

Claim 28. (New) The compound of claim 8 wherein R^6 is selected from the group consisting of hydrogen and halogen.

Claim 29. (New) The compound of claim 9 wherein R^7 is selected from the group consisting of hydrogen and halogen.

Claim 30. (New) The compound of claim 10 wherein R^8 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, halogen, halo- C_{1-6} -alkyl, and NR^xR^y wherein R^x is hydrogen and R^y is C_{1-6} -alkyl.

Claim 31. (New) The compound of claim 30 wherein R^8 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, halogen, and halo- C_{1-6} -alkyl.

Claim 32. (New) The compound of claim 11 wherein R^9 is hydrogen.

Claim 33. (New) The method of claim 16 wherein the affective disorder is depression.

Claim 34. (New) A method for the treatment of an anxiety disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Claim 35. (New) The method of claim 34 wherein the anxiety disorder is selected from the group consisting of general anxiety disorder, social anxiety disorder, post traumatic

stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia.

Claim 36. (New) A pharmaceutical composition comprising a compound of claim 13 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier or diluent.

Claim 37. (New) A method for the treatment of an affective disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 13 or a pharmaceutically acceptable salt thereof.

Claim 38. (New) The method of claim 37 wherein the affective disorder is depression.

Claim 39. (New) A method for the treatment of an anxiety disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 13 or a pharmaceutically acceptable salt thereof.

Claim 40. (New) The method of claim 39 wherein the anxiety disorder is selected from the group consisting of general anxiety disorder, social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia.